Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

NCT04637763 is registered in ClinicalTrials.gov with Caribou Biosciences, Inc. as lead sponsor.

NCT NCT04637763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04637763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Lead sponsor
Caribou Biosciences, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
May 26, 2021
Completion date
September 30, 2025
Enrollment
72 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma, b cell non-hodgkin's lymphoma, lymphoma, lymphoma, non-hodgkin, non hodgkin lymphoma, refractory b-cell non-hodgkin lymphoma, relapsed non hodgkin lymphoma